%0 Journal Article %1 Gu:2015:Nat-Genet:25485837 %A Gu, L %A Frommel, S C %A Oakes, C C %A Simon, R %A Grupp, K %A Gerig, C Y %A Bär, D %A Robinson, M D %A Baer, C %A Weiss, M %A Gu, Z %A Schapira, M %A Kuner, R %A Sültmann, H %A Provenzano, M %A ICGC Project on Early Onset Prostate Cancer, %A Yaspo, M L %A Brors, B %A Korbel, J %A Schlomm, T %A Sauter, G %A Eils, R %A Plass, C %A Santoro, R %D 2015 %J Nat Genet %K ABI-DKFZ %N 1 %P 22-30 %R 10.1038/ng.3165 %T BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence %U http://www.ncbi.nlm.nih.gov/pubmed/25485837 %V 47 %X Prostate cancer is driven by a combination of genetic and/or epigenetic alterations. Epigenetic alterations are frequently observed in all human cancers, yet how aberrant epigenetic signatures are established is poorly understood. Here we show that the gene encoding BAZ2A (TIP5), a factor previously implicated in epigenetic rRNA gene silencing, is overexpressed in prostate cancer and is paradoxically involved in maintaining prostate cancer cell growth, a feature specific to cancer cells. BAZ2A regulates numerous protein-coding genes and directly interacts with EZH2 to maintain epigenetic silencing at genes repressed in metastasis. BAZ2A overexpression is tightly associated with a molecular subtype displaying a CpG island methylator phenotype (CIMP). Finally, high BAZ2A levels serve as an independent predictor of biochemical recurrence in a cohort of 7,682 individuals with prostate cancer. This work identifies a new aberrant role for the epigenetic regulator BAZ2A, which can also serve as a useful marker for metastatic potential in prostate cancer.

@article{Gu:2015:Nat-Genet:25485837, abstract = {Prostate cancer is driven by a combination of genetic and/or epigenetic alterations. Epigenetic alterations are frequently observed in all human cancers, yet how aberrant epigenetic signatures are established is poorly understood. Here we show that the gene encoding BAZ2A (TIP5), a factor previously implicated in epigenetic rRNA gene silencing, is overexpressed in prostate cancer and is paradoxically involved in maintaining prostate cancer cell growth, a feature specific to cancer cells. BAZ2A regulates numerous protein-coding genes and directly interacts with EZH2 to maintain epigenetic silencing at genes repressed in metastasis. BAZ2A overexpression is tightly associated with a molecular subtype displaying a CpG island methylator phenotype (CIMP). Finally, high BAZ2A levels serve as an independent predictor of biochemical recurrence in a cohort of 7,682 individuals with prostate cancer. This work identifies a new aberrant role for the epigenetic regulator BAZ2A, which can also serve as a useful marker for metastatic potential in prostate cancer.}, added-at = {2015-06-29T14:32:37.000+0200}, author = {Gu, L and Frommel, S C and Oakes, C C and Simon, R and Grupp, K and Gerig, C Y and B{\"a}r, D and Robinson, M D and Baer, C and Weiss, M and Gu, Z and Schapira, M and Kuner, R and S{\"u}ltmann, H and Provenzano, M and {ICGC Project on Early Onset Prostate Cancer} and Yaspo, M L and Brors, B and Korbel, J and Schlomm, T and Sauter, G and Eils, R and Plass, C and Santoro, R}, biburl = {https://www.bibsonomy.org/bibtex/2e1a31ecb2c04afbf37e1d6b170f433ea/juraeva}, doi = {10.1038/ng.3165}, interhash = {91f7b15b93eb0fb7d0886dcf98036314}, intrahash = {e1a31ecb2c04afbf37e1d6b170f433ea}, journal = {Nat Genet}, keywords = {ABI-DKFZ}, month = jan, number = 1, pages = {22-30}, pmid = {25485837}, timestamp = {2015-06-29T14:34:20.000+0200}, title = {BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence}, url = {http://www.ncbi.nlm.nih.gov/pubmed/25485837}, volume = 47, year = 2015 }